Teriparatide. Osteoporosis: Less well evaluated than alendronic acid

Prescrire International

Volumn 14, Issue 75, 2005, Pages 5-9

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIZZINESS; DRUG DOSE REGIMEN; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; DRUG STORAGE; FEMALE; FRAGILITY FRACTURE; FREEZING; HEADACHE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; HYPOTHYROIDISM; INCIDENCE; KIDNEY DISEASE; LUNG EMBOLISM; MUSCLE CRAMP; NAUSEA; NONHUMAN; OSTEOSARCOMA; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; RARE DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SPINAL PAIN; STROKE; SYRINGE; THROMBOEMBOLISM; UREMIA; VEIN THROMBOSIS; VERTEBRA FRACTURE; WRIST FRACTURE; ANIMAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HORMONE SUBSTITUTION; MALE; PATHOLOGIC FRACTURE; RANDOMIZED CONTROLLED TRIAL; RAT; RISK FACTOR; SPINE FRACTURE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ALENDRONATE; ANIMALS; BONE DENSITY; CLINICAL TRIALS; DRUG COMBINATIONS; FEMALE; FRACTURES, SPONTANEOUS; HORMONE REPLACEMENT THERAPY; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RATS; RISK FACTORS; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 14544292469     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cauley JA et al. "Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Inifiafive randomized trial" JAMA 2003; 290 (13): 1729-1738.
2. Prescrire Editorial Staff "Postmenopausal hormone therapy: cardiovascular risk" Prescrire Int 2003; 12 (64): 65-69.
3. Prescrire Rédaction "Traitement hormonal substitutif de la ménopause et cancer, attention au sein" Rev Prescrire 2003; 23 (235): 28.
4. Prescrire Editorial Staff "Postmenopausal replacement therapy (continued)" Prescrire Int 2004; 24 (246): 25-28.
5. Prescrire Editorial Staff "Raloxifene" Prescrire Int 1999; 8 (44): 165-167.
6. Prescrire Editorial Staff "Raloxifene and prevention of vertebral fracture" Prescrire Int 2000; 9 (50): 190-191.
7. Prescrire Rédaction "acide alendronique - Fosamax°. Le nouveau libellé d'AMM n'est qu'un tour de passe-passe" Rev Prescrire 2001; 21 (220): 573.
8. Prescrire Rédaction "acide risédronique - Actonel°. 3e diphosphonate par voie orale pour la prévention des fractures ostéoporotiques" Rev Prescrire 2001; 21 (220): 570-573.
9. Prescrire Editorial Staff "Alendronic add 70 mg weekly" Prescrire Int 2003; 12 (66): 140.
10. Prescrire Rédaction "acide risédronique - Actonel°. Nouveau dosage pour une prise par semaine, pas mieux que l'acide alendronique" Rev Prescrire 2003; 23 (244): 732-733.
11. Meunier PJ "Traitement de l'ostéoporose postménopausique par les agents anaboliques" Rev Rhum 2001; 68: 944-950.
12. Fox J "Developments in parathyroid hormon and related peptides as bone-formation agents" Curr Opin Pharmacol 2002; 2: 338-344.
13. Rubin MR et al. "The anabolic effects of parathyroid hormone" Osteoporosis Int 2002; 13: 267-277.
14. Lilly Research Laboratories "Teriparatide injection - NDA21-318. Endocrinologic and metabolic drugs - Advisor committee briefing document - volume 1" 15 June 2001: 128 pages.
15. The European Agency for the Evaluation of Medicinal Products - Committee for Proprietary Medicinal Products - European Public Assessment Report (EPAR) "Forsteo - Scientific discussion" 27 June 2003: 22 pages.
16. Neer RM et al. "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post menopausal women with osteoporosis" N Engl J Med 2001; 344: 1434-1441.
17. Body JJ et al. "A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in post menopausal women with osteoporosis" J Clin Endocrinol Metab 2002; 87 (10): 4528-4535 + 88 (3): 1402-1403.
18. Food and Drug Administration "NDA 21-318: LY333 334 (Teriparatide) for osteoporosis. Medical safety review" undated: 33 pages.
19. Potts JT "Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders". In: Braunwald E et al. "Harrison's principles of internal medicine" 15th ed, McGraw-HilL New York 2001: 2205-2226.
20. Prescrire Editorial Staff "Etidronate" Prescrire Int 1994; 3 (14): 174.
21. Prescrire Editorial Staff "Very late withdrawal of fluorides" Prescrire Int 2002; 11 (59): 92.
22. Black DM et al. "The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis" N Engl J Med 2003; 349 (13): 1207-1215.
23. Rittmaster RS et al. "Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate" J Clin Endocrinol Metab 2000; 85 (6): 2129-2134.
24. Deal C and Gideon J "Recombinant human PTH 1-34 (Forteo°): an anabolic drug for osteoporosis" Cleveland Clin J Med 2003; 70 (7): 585-601.